Cannabis Global (CBGL) 10-Q 19 Apr 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Feb. 28, 2022	Apr. 19, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Feb. 28, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--08-31
Entity File Number	000-27039
Entity Registrant Name	CANNABIS GLOBAL, INC.
Entity Central Index Key	0001413488
Entity Tax Identification Number	83-1754057
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	520 S. Grand Avenue
Entity Address, Address Line Two	Ste. 320
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90071
City Area Code	(310)
Local Phone Number	986-4929
Title of 12(b) Security	Common
Trading Symbol	CBGL
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		509,142,691

CONSOLIDATED BALANCE SHEET (Una

CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Current Assets:
Cash	$ 604,001	$ 30,813
Accounts Receivable	451,577	113,379
Notes Receivable, Current	21,000	100,800
Inventory	195,548	189,081
Other Current Asset	10,496	7,992
Total Current Asset	1,282,622	442,065
Machinery & Equipment- Net	1,015,545	218,535
Other Assets
Long-Term Investments	407,000	650,000
Intangible Assets	3,870,000	500,000
Right of Use Asset	599,767	634,637
Goodwill	7,925,000	8,842,967
Notes Receivable	41,000	41,000
Security Deposit	7,200	9,600
TOTAL ASSETS	15,148,134	11,338,804
Current Liabilities:
Accounts Payable	744,397	730,825
Accounts Payable - Related Party	2,639	2,639
Accrued Interest	147,106	212,202
Due to Joint Venture	0	135,000
Notes Payable, Current	890,441	975,043
Right of Use Liability, Current	75,417	71,754
Convertible Notes, Net of Debt Discount of $821,015 and $734,579, respectively	748,815	1,206,708
Convertible Notes – Related Party, Net of Debt Discount of $124,164 and $721,393, respectively	1,129,992	408,607
Series B Convertible Preferred Stock, 1,000,000 shares authorized, 277,750 and 367,750 shares issued and outstanding	172,392	148,775
Derivative Liability	1,942,485	4,747,614
Notes Payable - Related Party	108,039	108,039
Total Current Liabilities	5,961,723	8,747,206
Right of Use Liability, Long-Term	524,350	562,997
Notes Payable	731,025	672,794
Total Liabilities	7,217,098	9,982,997
Stockholder's Equity
Preferred Stock, par value $0.0001, 10,000,000 shares Authorized, 6,000,000 shares Issued and Outstanding at February 28, 2022 and August 31, 2021	600	600
Common Stock, par value $0.001, 3,000,000,000 shares Authorized, 509,142,691 shares Issued and Outstanding at February 28, 2022 and 84,940,028 at August 31, 2021, respectively	509,141	84,938
Additional Paid-in Capital	16,995,195	11,591,829
Shares to be issued	2,078	2,078
Accumulated Deficit	(14,015,507)	(13,891,788)
Total Stockholder's Equity (Deficit) Attributable to Cannabis Global, Inc.	3,491,507	(2,212,343)
Noncontrolling Interest	4,439,529	3,568,150
Total Stockholder's Equity	7,931,036	1,355,807
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY	$ 15,148,134	$ 11,338,804

CONSOLIDATED BALANCE SHEET (U_2

CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Convertible Notes, Debt Discount Current	$ 821,015	$ 734,579
Convertible Notes Related Party, Debt Discount Current	$ 124,164	$ 721,393
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	6,000,000	6,000,000
Preferred stock, shares outstanding	6,000,000	6,000,000
Preferred stock, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, par or stated value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	509,142,691	84,940,028
Common stock, shares outstanding	509,142,691	84,940,028
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	277,750	367,750
Preferred stock, shares outstanding	277,750	367,750

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Revenue:
Total Revenue	$ 627,390	$ 25,816	$ 1,196,952	$ 30,226
Cost of Goods Sold	767,896	6,653	1,223,864	7,953
Gross Profit	(140,506)	19,163	(26,912)	22,273
Operating Expenses:
Advertising Expenses	14,644	(498)	23,963	50,524
Consulting Services	6,500	20,750	6,500	252,051
Professional Fees	122,337	129,263	271,074	179,895
General and Administrative Expenses	794,743	282,056	971,527	396,492
Total Operating Expenses	938,224	431,571	1,273,064	878,962
Operating Loss	(1,078,730)	(412,408)	(1,299,976)	(856,689)
Other Income (Expense)
Interest Expense	(2,487,747)	(1,933,728)	(3,743,233)	(2,706,483)
Changes in FV of Derivatives	1,715,626	593,235	3,488,560	1,308,912
Other Income	0	1,522	0	1,642
Loss on impairment	(60,000)	0	(60,000)	0
Loss on settlement	(165,000)	0	(165,000)	0
Gain (loss) on investment	(10,909)	0	60,967	0
Gain on acquisition	454,768	0	454,768	0
Equity method income (loss)	934,867	(359,391)	934,867	(211,376)
Total Other Income (Expense)	381,605	(1,698,362)	970,929	(1,607,305)
Net Loss	(697,125)	(2,100,770)	(329,047)	(2,463,994)
Net income attributable to noncontrolling interest	193,701	0	205,328	0
Net loss attributable to Cannabis Global, Inc.	$ (503,424)	$ (2,110,770)	$ (123,719)	$ (2,463,994)
Basic Loss per Common Share	$ 0	$ (0.05)	$ 0	$ (0.06)
Diluted Loss per Common Share	$ 0	$ (0.05)	$ 0	$ (0.06)
Weighted Average Common Shares
Outstanding - Basic	271,165,969	43,196,439	233,056,112	39,744,494
Weighted Average Common Shares
Outstanding - Diluted	271,165,969	43,196,439	233,056,112	39,744,494
Product [Member]
Revenue:
Total Revenue	$ 627,390	$ 25,816	$ 1,196,952	$ 30,226

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Class A Preferred Stock [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Stockholders Equity Attributable To Cannabis Global Inc [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Aug. 31, 2020	$ 600	$ 2,708	$ 187	$ 4,618,168	$ (6,056,949)	$ (1,435,286)		$ (1,435,286)
Beginning Balance, Shares at Aug. 31, 2020	6,000,000	27,082,419	1,871,858
Stock based compensation		$ 3,400		179,600		183,000		183,000
Stock based compensation, Share		3,400,000
Proceeds from common stock subscriptions		$ 510	$ 90	(600)
Proceeds from common stock subscriptions, Shares		510,204	89,796
Common stock issued for investment		$ 7,222		642,778		650,000		650,000
Common stock issued for investment, Shares		7,222,222
Common stock issued in settlement of convertible notes payable and accrued interest		$ 1,500		28,500		30,000		30,000
Common stock issued in settlement of convertible notes payable and accrued interest, Shares		1,500,000
Effects of Par value adjustment		$ 24,372	1,683	(26,055)
Net Loss					(353,224)	(353,224)		(353,224)
Ending balance, value at Nov. 30, 2020	$ 600	$ 39,712	$ 1,960	5,442,391	(6,410,173)	(925,510)		(925,510)
Ending Balance, Shares at Nov. 30, 2020	6,000,000	39,714,845	1,961,654
Stock based compensation		$ 4,107	$ (600)	335,827		339,334		339,334
Stock based compensation, Share		4,106,543	(600,000)
Proceeds from common stock subscriptions		$ 6,517		384,483		391,000		391,000
Proceeds from common stock subscriptions, Shares		6,516,667
Common stock issued for investment		$ 12,820		2,209,355		2,222,175	3,849,293	6,071,468
Common stock issued for investment, Shares		12,820,297
Common stock issued in settlement of convertible notes payable and accrued interest		$ 3,047		213,682		216,729		216,729
Common stock issued in settlement of convertible notes payable and accrued interest, Shares		3,047,335
Derivative impact of conversions				276,975		276,975		276,975
Net Loss					(2,110,770)	(2,110,770)		(2,110,770)
Ending balance, value at Feb. 28, 2021	$ 600	$ 66,203	$ 1,360	8,862,713	(8,520,943)	409,933	3,849,293	4,259,226
Ending Balance, Shares at Feb. 28, 2021	6,000,000	66,205,687	1,361,654
Beginning balance, value at Aug. 31, 2021	$ 600	$ 84,938	$ 2,078	11,591,829	(13,891,788)	(2,212,343)	3,568,150	1,355,807
Beginning Balance, Shares at Aug. 31, 2021	6,000,000	84,940,028
Stock based compensation		$ 3,327		86,047		89,374		89,374
Stock based compensation, Share		3,326,790
Common stock issued in settlement of convertible notes payable and accrued interest		$ 124,188		933,554		1,057,742		1,057,742
Common stock issued in settlement of convertible notes payable and accrued interest, Shares		124,187,672
Derivative impact of conversions				1,273,832		1,273,832		1,273,832
Net Loss					379,705	379,705	(11,627)	368,078
Ending balance, value at Nov. 30, 2021	$ 600	$ 212,453	$ 2,078	13,885,262	(13,512,083)	588,310	3,556,523	4,144,833
Ending Balance, Shares at Nov. 30, 2021	6,000,000	212,454,490	2,079,654
Common stock issued in settlement of convertible notes payable and accrued interest		$ 195,388		371,671		567,059		567,059
Common stock issued in settlement of convertible notes payable and accrued interest, Shares		195,388,201
Common stock issued related to joint venture		$ 75,000		225,000		300,000		300,000
Common stock issued related to joint venture, Shares		75,000,000
Discount on convertible notes		$ 3,000		22,200		25,200		25,200
Discount on convertible notes, Shares		3,000,000
Common stock issued in exchange for exercise of warrants on a cashless basis		$ 23,300		(23,300)
Common stock issued in exchange for exercise of warrants on a cashless basis, Shares		23,300,000
Acquisition measurement period adjustment				1,729,253		1,729,253	1,076,707	2,805,960
Derivative impact of conversions				785,109		785,109		785,109
Net Loss					(503,424)	(503,424)	(193,701)	(697,125)
Ending balance, value at Feb. 28, 2022	$ 600	$ 509,141	$ 2,078	$ 16,995,195	$ (14,015,507)	$ 3,491,507	$ 4,439,529	$ 7,931,036
Ending Balance, Shares at Feb. 28, 2022	6,000,000	509,142,691	2,079,654

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (329,047)	$ (2,463,994)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-Cash Interest Expense	3,443,624	2,342,280
Realized Gain on Investments	(60,967)	0
Joint venture settlement	165,000	0
Impairment loss	60,000	0
Gain on acquisition accounting	(454,768)	0
Equity Method (Income) Loss From Investments	(934,868)	211,376
Depreciation Expense	892,955	1,798
Stock Based Compensation	89,374	522,334
Changes in Fair Value of Derivative Liabilities	(3,488,560)	(1,308,912)
Right of Use Asset Amortization	34,870	0
Changes In:
Accounts Receivable	(338,198)	(24,767)
Other Current Assets	(2,504)	0
Inventory	166,033	(104,817)
Other Asset	82,200	0
Accounts Payable and Accrued Expenses	65,896	(61,053)
Accrued Interest	190,227	111,311
Right of Use Lease Liability	(34,984)	0
Net Cash Used in Operating Activities	(453,717)	(774,444)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash acquired in acquisition	0	2,200
Purchase of property, plant and equipment	(6,402)	0
Sale of Marketable Securities	303,967	0
Net Cash Provided by Investing Activities	297,565	2,200
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Convertible Debentures	1,065,320	1,086,000
Proceeds from issuance of common stock	0	391,000
Repayment of Convertible Notes Payable	(137,109)	(578,000)
Repayment of Convertible Notes Payable	45,000	5,093
Repayment of Notes Payable	(243,871)	0
Net Cash Provided by Financing Activities	729,340	904,093
Net Increase in Cash	573,188	131,849
Cash at Beginning of Period	30,813	2,338
Cash at End of Period	604,001	134,187
Cash paid during the year for:
Interest	81,838	188,292
Taxes	0	0
Shares issued and loan incurred for acquisition of intangible assets	0	650,000
Inventory acquired with short term note payable	172,500	0
Shares issued for Conversion of Notes Payable and Accrued Interest	1,357,742	246,729
Common stock issued for acquisition of NPE	0	2,222,175
Increase in noncontrolling interest from acquisition of NPE	0	3,849,293
Common stock issued related to joint venture	300,000	0
Discount on convertible notes	25,200	0
Acquisition measurement period adjustment	$ 2,805,960	$ 0

Organization and Description of

Organization and Description of Business	6 Months Ended
	Feb. 28, 2022
Accounting Policies [Abstract]
Organization and Description of Business	Note 1. Organization and Description of Business Cannabis Global, Inc. is located at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071. Our telephone number is (310) 986-4929 and our website is accessible at www.cannabisglobalinc.com. Our shares of Common Stock are quoted on the OTC Markets Pink Tier, operated by OTC Markets Group, Inc., under the ticker symbol “CBGL.” Historical Development We incorporated in Nevada in 2005 under the name MultiChannel Technologies Corporation, a wholly owned subsidiary of Octillion Corporation, a development stage technology company focused on the identification, acquisition and development of emerging solar energy and solar related technologies. In April, 2005, we changed our name to MicroChannel Technologies, Inc., and in June, 2008, began trading on the OTC Markets under the trading symbol “MCTC.” Our business focused on research and development of a patented intellectual properties combining physical, chemical, and biological cues at the “cellular” level to facilitate peripheral nerve regeneration. On June 27, 2018, we changed domiciles from the State of Nevada to the State of Delaware, and thereafter reorganized under the Delaware Holding Company Statute. On or about July 12, 2018, we formed two subsidiaries for the purpose of effecting the reorganization. We incorporated MCTC Holdings, Inc. and MCTC Holdings Inc. incorporated MicroChannel Corp. We then effected a merger involving the three constituent entities, and under the terms of the merger we were merged into MicroChannel Corp., with MicroChannel Corp. surviving and our separate corporate existence ceasing. Following the merger, MCTC Holdings, Inc. became the surviving publicly traded issuer, and all of our assets and liabilities were merged into MCTC Holdings, Inc.’s wholly owned subsidiary MicroChannel Corp. Our shareholders became the shareholders of MCTC Holdings, Inc. on a one for one basis. On May 25, 2019, Lauderdale Holdings, LLC, a Florida limited liability company, and beneficial owner 70.7 130,000,000 43,333,333 108,333 325,000 On August 9, 2019, we filed a DBA in California registering the operating name Cannabis Global. On July 1, 2019, the Company entered into a 100% business acquisition with Action Nutraceuticals, Inc., a company owned by our CEO, Arman Tabatabaei in exchange for $ 1,000 Effective as of September 30, 2019, we affected a reverse split of our common shares effective as at the rate of 1:15. On September 11, 2019, we formed a subsidiary Aidan & Co, Inc. (“Aidan”) a California corporation as a wholly owned subsidiary of the Company. Aidan will be engaged in various related business opportunities. At this time Aidan has no operations. On December 4, 2019, our shareholders approved and authorized (i) re-domiciling the Company from Delaware to Nevada; (ii) changing the name of the Company from MCTC Holdings, Inc. to Cannabis Global, Inc.; and, (iii) seeking a corresponding change of name and new trading symbol for the Company with FINRA. On March 30, 2020, we filed Articles of Conversion with the Delaware Secretary of State, electing to convert and re-domicile the Company from a Delaware corporation to a newly formed Nevada corporation named Cannabis Global, Inc. Concurrently, the Registrant filed Articles of Incorporation and Articles of Domestication with the Nevada Secretary of State incorporating the Registrant in Nevada under the name Cannabis Global, Inc. and accepting the re-domicile of Registrant’s Delaware corporation. There was no change to the Registrant’s fiscal year end. As a result of our FINRA corporate action, our name was changed to Cannabis Global, Inc. and our trading symbol changed to “CBGL.” On April 18, 2020, we formed a subsidiary Hemp You Can Feel, Inc., a California corporation (“HYCF”), as a wholly owned subsidiary of the Company. HYCF will be engaged in various related business opportunities. At this time HYCF has no operations. On May 6, 2020, we signed a joint venture agreement with RxLeaf, Inc. (“RxLeaf”) a Delaware corporation, creating a joint venture for the purpose of marketing the Company’s products to consumers. Under the terms of the agreement, the Company will produce products, which will be sold by RX Leaf via its digital marketing assets. The Company agreed to share the profits from the joint venture on a 50/50 basis. As of the date of this filing, the joint venture has no operations. On July 22, 2020, we signed a management agreement with Whisper Weed, Inc., a California corporation (“Whisper Weed”). Edward Manolos, our director, is a shareholder in Whisper Weed (see “Related Party Transactions”). Whisper Weed conducts licensed delivery of cannabis products in California. The material definitive agreement requires the parties to create a separate entity, CGI Whisper W, Inc. in California as a wholly owned subsidiary of the Company. The business of CGI Whisper W, Inc. will be to provide management services for the lawful delivery of cannabis in the State of California. The Company will manage CGI Whisper W, Inc. operations. In exchange for the Company providing management services to Whisper Weed through the auspices of CGI Whisper W, Inc., the Company will receive as consideration a quarterly fee of 51% of the net profits earned by Whisper Weed. As separate consideration for the transaction, the Company agreed to issue to Whisper Weed $ 150,000 On August 31, 2020, we entered into a stock purchase agreement with Robert L. Hymers III (“Hymers”). Pursuant to the Stock Purchase Agreement, the Company purchased from Hymers 266,667 2,040,000 On September 30, 2020, the Company entered into a securities exchange agreement with Marijuana Company of America, Inc., a Utah corporation (“MCOA”). By virtue of the agreement, the Company issued 7,222,222 650,000,000 650,000 618,000 303,967 60,967 On November 16, 2020, we entered into a business acquisition agreement with Ethos Technology LLC, dba Comply Bag, a California limited liability company (“Ethos”). Ethos is a business in the market for cannabis trackable storage bags. By virtue of the agreement, Ethos sold, assigned, and transferred to the Company all of Ethos’ business, including all of its assets and associated liabilities, in exchange for the Company’s issuance of an aggregate of 6,000,000 1,500,000 1,500,000 1,500,000 3,000,000 177,000 1,500,000 1,500,000 On January 27, 2021, we closed a material definitive agreement (MDA) with Edward Manolos, our director and related party. Pursuant to the MDA, the Company purchased from Mr. Manolos 266,667 2,040,000 11,383,929 On February 16, 2021, we purchased 266,667 1,436,368 On May 12, 2021, The Company and Marijuana Company of America (MCOA) agreed to operate a joint venture through a new Nevada corporation named MCOA Lynwood Services, Inc. The parties agreed to finance a regulated and licensed laboratory to produce various cannabis products under the legal framework outlined by the City of Lynwood, California, Los Angeles County, and the State of California. We own a controlling interest in Natural Plant Extract of California, Inc., which operates a licensed cannabis manufacturing operation in Lynwood, California. As its contribution the joint venture, MCOA agreed to purchase and install equipment for joint venture operations, which will then be rented to the joint venture, and also provide funding relating to marketing the products produced by the capital equipment. We agreed to provide use of our manufacturing and distribution licenses; access to the Lynwood, California facility; use of the specific areas within the Lynwood Facility suitable for the types of manufacturing selected by the joint venture; and, management expertise require to carry on the joint venture’s operations. Our ownership of the joint venture was agreed to be 60% and 40% with MCOA. Royalties from profits realized as the result of sales of products from the joint venture were also agreed to be distributed as 60% to us and 40% to MCOA. MCOA contributed $ 135,000 75,000,000 135,000 165,000 Current Business Operations Cannabis Global manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc., sells the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. We recently announced our acquisition of a 56.5%, controlling interest in Natural Plant Extract (NPE), which operates a licensed cannabis manufacturing and distribution business in Lynwood, California, holding a Type 7 California Manufacturing and a distribution license, allowing for cannabis product distribution anywhere in the state. We plan to use the Lynwood NPE operation, combined with our internally developed technologies, as a testbed to launch multi-state operations as soon as possible if cannabis is removed as a Scheduled substance from the federal Controlled Substances Act (“CSA”), and interstate commerce in cannabis is approved by the federal government. As of the date of this filing, cannabis remains a Schedule 1 controlled substance and so illegal under the CSA. Our operations at the Natural Plant Extract facility emphasizes regulated cannabis product manufacturing and distribution. In addition to business opportunities available from regulated cannabis product manufacturing and distribution to all parts of the State of California, we also see strong synergies between NPE operations and sales of our Ethos technology Comply Bag, and our developing technologies including the areas of cannabis infusions, and all-natural polymeric nanoparticle technologies. We also have an active research and development program primarily focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Additionally, we invest, or provide managerial services, in specialized areas of the regulated hemp and cannabis industries. Thus far, the Company has filed six provisional patents, three non-provisional patents and recently announced its "Comply Bag" secure cannabis transport system with integrated track and trace capabilities via smartphones, which is available for purchase now. On April 9, 2021, we entered into a distribution agreement with Lynwood Roads Delivery, LLC (“LDR”). LRD owns a regulatory permit issued by the City of Lynwood permitting commercial retailer non-storefront operation in Lynwood, California. Under the terms of the agreement, the Company’s majority owned subsidiary, Natural Plant Extract of California, via is licensed Northern Lights Distribution, Inc. operation will distribute selected products for LDR. On April 21, 2021, The Company began taking orders for its new product lines produced at the NPE facility, completing its initial product development phase. On May 12, 2021, we entered into an agreement to operate a joint venture through a new Nevada corporation named MCOA Lynwood Services, Inc. The parties agreed to finance a regulated and licensed laboratory to produce various cannabis products under the legal framework outlined by the City of Lynwood, California, Los Angeles County, and the State of California. The Registrant owns a controlling interest in Natural Plant Extract of California, Inc., which operates a licensed cannabis manufacturing operation in Lynwood, California. As its contribution the joint venture, MCOA agreed to purchase and install equipment for joint venture operations, which will then be rented to the joint venture, and also provide funding relating to marketing the products produced by the capital equipment. We agreed to provide use of NPE’s manufacturing and distribution licenses; access to its Lynwood, California facility; use of the specific areas within the Lynwood Facility suitable for the types of manufacturing selected by the joint venture; and, management expertise require to carry on the joint venture’s operations. Ownership of the joint venture was agreed to be 60% in us and 40% with MCOA. Royalties from profits realized as the result of sales of products from the joint venture was also agreed to be distributed as 60% to us and 40% to MCOA. Development of the joint venture is ongoing and is considered in the development stage. On January 26, 2022, the Company and MCOA entered into a settlement agreement, whereby the Company agreed to issue MCOA 75,000,000 shares of common stock. As of the date of this filing, the joint venture is in the development stage. Our research and development programs included the following: 1. Development of new routes and vehicles for hemp extract and cannabinoid delivery to the human body. 2. Production of unique polymeric nanoparticles and fibers for use in oral and dermal cannabinoid delivery. 3. Research and commercialization of new methodologies to isolate and/or concentrate various cannabinoids and other substances that comprise industrial hemp oil and other extracts. 4. Establishment of new methods to increase the bioavailability of cannabinoids to the human body utilizing nanoparticles and other proven bioenhancers, including naturally occurring and insect produced glycosides. 5. Development of other novel inventions for the delivery of cannabinoids to the human body, which at this time are considered trade secrets by the Company.

Going Concern Uncertainties

Going Concern Uncertainties	6 Months Ended
	Feb. 28, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainties	Note 2. Going Concern Uncertainties The Company has an accumulated deficit of $ 14,015,507 329,047 453,717 The Company’s ability to continue as a going concern is an issue due to its net losses and negative cash flows from operations, and its need for additional financing to fund future operations. Management plans to obtain necessary funding from outside sources and through the sales of Company shares. There can be no assurance that such funds, if available, can be obtained on terms reasonable to the Company. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty. Based on the Company’s current level of expenditures, management believes that cash on hand is not adequate to fund operations for the next twelve months. Management of the Company is estimating approximately $2,500,000 will be required over the next twelve months to fully execute its business strategy. These can be no assurance the Company will be able to obtain such funds.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Feb. 28, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts reported in those statements. We have made our best estimates of certain amounts contained in our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. However, application of our accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties, and, as a result, actual results could differ materially from these estimates. Management believes that the estimates, assumptions, and judgments involved in the accounting policies described below have the most significant impact on our consolidated financial statements. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Derivative Instruments The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in the fair value of derivatives liability are recorded in the consolidated statement of operations under non-operating income (expense). We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, we use a weighted average Binomial option-pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and NPE, in which the Company controls 56.4% of the common stock. All intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution. Inventory Inventory is primarily comprised of work in progress. Inventory is valued at cost, based on the specific identification method, unless and until the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to market value. As of February 28, 2022, and August 31, 2021, market values of all of our inventory were at cost, and accordingly, no Deposits Deposits is comprised of advance payments made to third parties, primarily for inventory for which we have not yet taken title. When we take title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale (see “Costs of Revenues” below). There were no Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets is primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods, which approximate the life of the contract or service period. Accounts Receivable Accounts receivables are recorded at the net value of face amount less any allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and, based on a method of specific identification of any accounts receivable for which we deem the net realizable value to be less than the gross amount of accounts receivable recorded, we establish an allowance for doubtful accounts for those balances. In determining our need for an allowance for doubtful accounts, we consider historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate, resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that we collect retainers from our clients prior to performing significant services. The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of February 28, 2022, and August 31, 2021, we had $ 0 Property and Equipment, net Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Depreciation of capitalized construction in progress costs, a component of property and equipment, net, begins once the underlying asset is placed into service and is recognized over the estimated useful life. Property and equipment are reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” Accounting for the Impairment of Long-Lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. Beneficial Conversion Feature If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). We record a BCF as a debt discount pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ACF”) Topic 470-20 Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and we amortize the discount to interest expense over the life of the debt using the effective interest method. Revenue Recognition For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The guidance presents a single five-step model for comprehensive revenue recognition that requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Two options are available for implementation of the standard which is either the retrospective approach or cumulative effect adjustment approach. The guidance becomes effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We determined to implement the cumulative effect adjustment approach to our implementation of FASB ASC Topic 606, with no restatement of the comparative periods presented. We intend to apply this method to any incomplete contracts we determine are subject to FASB ASC Topic 606 prospectively. As is more fully discussed below, we are of the opinion that none of our contracts for services or products contain significant financing components that require revenue adjustment under FASB ASC Topic 606. In accordance with FASB ASC Topic 606, Revenue Recognition, we will recognize revenue when persuasive evidence of a significant financing component exists in our consulting and product sales contracts. We examine and evaluate when our customers become liable to pay for goods and services; how much consideration is paid as compared to the cash selling price of the goods or services; and, the length of time between our performance and the receipt of payment. Product Sales Revenue from product sales, including delivery fees, is recognized when an order has been obtained from the customer, the price is fixed and determinable when the order is placed, the product is shipped, and collectability is reasonably assured. For any shipments with destination terms, the Company defers revenue until delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606. Costs of Revenues Our policy is to recognize the costs of revenue in the same manner in conjunction with revenue recognition. Costs of revenues include the costs directly attributable to revenue recognition and include compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred. Stock-Based Compensation Restricted shares are awarded to employees and entitle the grantee to receive shares of restricted common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date. Stock-based compensation during the quarterly reporting periods ended February 28, 2022 and 2021 was $ 89,374 522,334 Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. For the quarterly reporting periods ending February 28, 2022 and 2021, we incurred no income taxes and had no liabilities related to federal or state income taxes. Loss Contingencies From time to time the Company is subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the balance sheet. If the Company determines that such an estimate cannot be made, the Company's policy is to disclose a demonstration of its attempt to estimate the loss or range of losses before concluding that an estimate cannot be made, and to disclose it in the notes to the financial statements under Contingent Liabilities. Net Income (Loss) Per Common Share We report net income (loss) per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net income (loss) per share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted net income (loss) per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Feb. 28, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Note 4. Net Income (Loss) Per Share 604,448,320 142,089,094

Intangible Assets

Intangible Assets	6 Months Ended
	Feb. 28, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5. Intangible Assets On February 20, 2020, the Company entered into a material definitive agreement with Lelantos Biotech, Inc., a Wyoming corporation (“Lelantos”), and its owners. On June 15, 2020, the Company and Lelantos entered into a modification agreement cancelling the Company's obligation to issue 400,000

Acquisition of Natural Plant Ex

Acquisition of Natural Plant Extract of California, Inc.	6 Months Ended
	Feb. 28, 2022
Acquisition Of Natural Plant Extract Of California Inc.
Acquisition of Natural Plant Extract of California, Inc.	Note 6. Acquisition of Natural Plant Extract of California, Inc. On August 31, 2020 we issued a convertible promissory note pursuant to a Stock Purchase Agreement (the “SPA) with Robert L. Hymers, III (“Hymers”) to acquire 266,667 4.99 10 270,886 1,714,903 On June 11, 2021, we amended the material definitive agreement with Hymers. The amendment relieved us from having to make monthly payments of $20,000 to Hymers in exchange for our issuing a convertible promissory note to Hymers for the balance owed of $ 440,000 On January 27, 2021, the Company acquired an additional 18.8% interest in NPE from Edward Manolos, a Director of the Company and a related party. The Company issued 11,383,929 shares of common stock, which had a fair value of $ 1,821,429 On February 16, 2021, we purchased 266,667 1,436,368 As a result of the transaction, we became party to a Shareholder Agreement with respect to our ownership over the NPE Shares, dated June 5, 2020, by and among Alan Tsai, Robert Hymers III, Betterworld Ventures, LLC (“BWV”), Marijuana Company of America, Inc. and NPE. The Joinder Agreement contains terms and conditions including, but not limited to: the ownership and management of NPE, rights of shareholders concerning the transfer of shares in NPE, pre-emptive rights, drag-along rights, confidentiality, and term and termination. The NPE acquisition is being accounted for as a business combination under ASC 805 as a result of the transfer of control. The following information summarizes the purchase consideration and allocation of the fair values assigned to the assets at the purchase date: Schedule of Preliminary Purchase Price Allocation Purchase Price Allocation: Cash 2,200 Accounts receivable 193,607 Notes receivable 162,247 Property and equipment 1,153,000 Right of use asset – operating lease 673,425 Trademarks and trade names, estimated 5 year life 300,000 Licenses, estimated 10 year life 1,500,000 Customer relationships, estimated 5 year life 2,300,000 Goodwill 7,925,000 Total assets acquired $ 14,209,479 Accounts payable and accrued expenses 289,591 Right of use liability – operating lease 673,425 Notes payable 1,825,101 Notes payable – related party 105,539 Total Liabilities Assumed $ 2,893,656 Immediately prior to obtaining control, our total investment in NPE was adjusted to the preliminary fair value of $ 3,324,956 359,391 934,868 4,926,000 454,768

Related Party Transactions

Related Party Transactions	6 Months Ended
	Feb. 28, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 7. Related Party Transactions Note Payable to Shareholders On May 25, 2019, we issued two notes payable to Company directors Edward Manolos and Dan Nguyen, each in the amount of $ 16,667 5 Related party Transactions In March 2018 and May 2018, a legal custodian of the Company funded the Company $ 600 10 On August 31, 2020, the Company issued a convertible note payable and a note payable to Robert L. Hymers III in connection with the acquisition of an 18.8% equity interest in NPE. See Note 9 and Note 6. On November 16, 2020, we entered into a business acquisition agreement with Ethos Technology LLC, dba Comply Bag, a California limited liability company (“Ethos”). Ethos is a development stage business in the process of entering the market for cannabis trackable storage bags. By virtue of the agreement, Ethos sold, assigned, and transferred to the Company all of Ethos’ business, including all of its assets and associated liabilities, in exchange for the Company’s issuance of an aggregate of 6,000,000 1,500,000 1,500,000 1,500,000 On November 16, 2020, the Company sold an aggregate 3,000,000 177,000 1,500,000 1,500,000 On January 27, 2021 the Company closed a material definitive agreement (MDA) with Edward Manolos, a director and related party. Pursuant to the MDA, the Company purchased from Mr. Manolos 266,667 11,383,929 On May 12, 2021, we entered into an agreement to operate a joint venture through a new Nevada corporation named MCOA Lynwood Services, Inc. Mr. Edward Manolos is a director of both parties to the agreement and this the agreement was an agreement between related parties. The parties agreed to finance a regulated and licensed laboratory to produce various cannabis products under the legal framework outlined by the City of Lynwood, California, Los Angeles County and the State of California. We own a controlling interest in Natural Plant Extract of California, Inc., which operates a licensed cannabis manufacturing operation in Lynwood, California. As its contribution the joint venture, MCOA agreed to purchase and install equipment for joint venture operations, which will then be rented to the joint venture, and also provide funding relating to marketing the products produced by the capital equipment. We agreed to provide use of its manufacturing and distribution licenses; access to its Lynwood, California facility; use of the specific areas within the Lynwood Facility suitable for the types of manufacturing selected by the joint venture; and, management expertise require to carry on the joint venture’s operations. Ownership of the joint venture was agreed to be 60% in us and 40% with MCOA. Royalties from profits realized as the result of sales of products from the joint venture was also agreed to be distributed as 60% in us and 40% to MCOA. Development of the joint venture is ongoing and is considered in the development stage. In January 2022, the Company agreed to issue 75,000,000 On May 12, 2021, we entered into a material definitive agreement not made in the ordinary course of its business. The parties to the material definitive agreement are the Registrant and Marijuana Company of America, Inc., a Utah corporation (“MCOA”). Mr. Edward Manolos is a director of both the Company and MCOA, and thus agreement is between related parties. Previously, on September 30, 2020, the Registrant and MCOA entered into a Share Exchange Agreement whereby the Registrant acquired that number of shares of MCOA’s common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date, in exchange for the number of shares of the Registrant’s common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date. For both parties, the Share Exchange Agreement contained a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of the parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. Complementary to the Share Exchange Agreement, Registrant and MCOA entered into a Lock-Up Agreement dated September 30, 2020 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance, and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month. On June 9, 2021, the parties amended their securities exchange agreement to delete the lock up leak out agreement, and the requirement to conduct quarterly reviews of each party’s respective stock price for purposes of evaluating whether additional share issuances are required to maintain the value of exchanged common shares equal to $ 650,000 618,000 303,967 60,967

Notes Payable

Notes Payable	6 Months Ended
	Feb. 28, 2022
Notes Payable
Notes Payable	Note 8. Notes Payable On February 12, 2020, the Company issued three Sellers Acquisition promissory notes having an aggregate principal amount of $ 500,000 May 31, 2020 8 50,747 450,000 76,438 450,000 55,824 On February 12, 2020, the Company entered into an Independent Consulting Agreement with a consultant to provide services from February 12, 2020 through December 14, 2020 (the “Consulting Agreement”). Pursuant to the Consulting Agreement, the Company issued to the consultant a Compensation promissory note having a principal amount of $ 100,000 100,000 14,400 100,000 12,405

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Feb. 28, 2022
Convertible Notes Payable
Convertible Notes Payable	Note 9. Convertible Notes Payable On January 12, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 115,500 0.10 100,000 115,500 40,000 3,112 On January 26, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 243,875 215,500 243,875 118,875 9,543 11,446,165 On January 26, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 243,875 215,500 243,875 15,000 2,250 208,191 228,875 14,307 27,063,391 On March 8, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 215,000 191,000 215,000 270,250 21,276 81,397,959 On March 16, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 215,000 191,000 215,000 215,000 12,372 30,087,611 On May 20, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 8 130,000 108,000 130,000 130,000 6,261 46,880,909 On June 16, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 8 135,000 108,000 130,000 47,560 2,440 14,912,584 28,262 4,069 0 On August 4, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 8 110,000 89,000 110,000 48,000 1957 21,910,886 On September 22, 2021, the Company entered into a $ 25,000 21,000 March 22, 2022 25,000 1,089 On January 3, 2022, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 100,000 80,000 3,000,000 25,200 120,000 15,342 84,658 1,584 On January 6, 2022, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 8 120,000 102,000 120,000 18,411 101,589 1,394 On February 11, 2022, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 8 130,000 110,400 130,000 19,945 110,055 484 On February 11, 2022, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 12 615,000 512,820 0.0025 615,000 94,356 520,644 3,437 Series B Convertible Preferred Stock On February 28, 2021 the Company filed a Certificate of Designation of Preferences, Rights of Series B Preferred Stock. The Series B Convertible Preferred stock has 1,000,000 shares authorized, has a par value of $0.001 per share and a stated value of $1.00. Each share of Series B Preferred Stock will carry an annual dividend in the amount of eight percent (8%) of the Stated Value (the “Divided Rate”), which shall be cumulative, payable solely upon redemption, liquidation or conversion. The Series B is convertible into shares of common stock at a rate of 63% of the market price, based on the average of the two lowest trading prices during the previous 15 days. Additionally, the Series B Convertible Preferred Stock is mandatorily redeemable 16 months from the issuance date in cash. Upon the occurrence of an Event of Default (as defined herein), the Dividend Rate shall automatically increase to twenty two percent (22%). Based on the terms of the Series B Preferred Stock Purchase Agreement, and in accordance with ASC 480-10, the instruments are accounted for as a liability. During the year ended August 31, 2021, the Company entered into five Series B Preferred Stock Purchase Agreements for an aggregate amount of $ 367,750 367,750 14,710 51,181,398 During the six months ended February 28, 2022, the Company entered into five Series B Preferred Stock Purchase Agreements for an aggregate amount of $ 277,500 260,000 260,000 As of February 28, 2022, the carrying value of the Series B Convertible Preferred Stock liability in aggregate was $ 172,142 105,358 24,336 As of February 28, 2022, there were 277,750 Related Parties During the three months ended February 29, 2020, the Company issued two convertible promissory notes having an aggregate principal amount of $ 133,101 79,333 53,768 10 133,101 79,333 2,608 694,902 10,468 15,884 37,884 3,138 53,768 4,626 878,190 On April 30, 2020, the Company entered into a settlement agreement with its former Chief Financial Officer (Robert L. Hymers III, hereinafter referred to as the “CFO”) whereby the CFO resigned and the Company issued a promissory note for $ 30,000 December 31, 2020 10 0.02 30,000 15,061 14,939 1,011 1,500,000 On August 21, 2020 the Company, issued a convertible note pursuant to a Stock Purchase Agreement (the “SPA) to acquire 266,667 540,000 270,886 1,714,903 690,000 86,203 Company authorized and entered into an exchange agreement with Mr. Hymers to exchange the remaining $690,000 principal and $164,156 of accrued interest into a new $854,156 note (“exchange note”). The exchange note is convertible at a fixed price of $0.0025 per share and matures on February 11, 2023. 854,156 2,476 The Company evaluated its interest in NPE as of August 31, 2020 under ASC 810. Management determined that it had a variable interest in NPE, but that NPE does not meet the definition of a variable interest entity, and does not have an indirect voting interest of greater than 50%. Based on these factors, the investment in NPE by the Company, the investment in NPE will be accounted for as an equity method investment under the measurement alternative available under ASC 321 with the Company recording its share of the profits and losses of NPE at each reporting period. The initial investment balance was $1,714,903 based on the initial fair value estimate of the note payable and convertible note payable issued as consideration for the investment. The Company subsequently acquired control of NPE and began consolidating the results of operations into its financial statements, as described in Note 7. As of August 31, 2021, the Company was in default of the $540,000 note payable to Robert Hymers. On January 3, 2021, the Company entered into a settlement agreement with Robert Hymers concerning five delinquent payments totaling $100,000, whereby 1,585,791 shares of common stock were issued in settlement of those payments. As of February 28, 2021, the Company missed five additionally $20,000 payments, and remains in default of this agreement. On June 11, 2021, the Company entered into an agreement with Robert Hymers. As of the date of the amendment, the Company owed Mr. Hymers $ 440,000 June 11, 2022 10 0.004 40,000 17,543,860 275,836 124,164 29,600 On December 28, 2021, the Company entered into a convertible note agreement with Robert Hymers, for $24,774 in settlement of outstanding accounts payable. The note was convertible at 55% of the lowest trading price of the Company’s common stock for the 15 days prior conversion. On December 29, 2021, the Company issued 10,475,053 24,774 See Note 10 for further discussion of the accounting treatment of the embedded conversion options of the above promissory notes payable as derivative liabilities.

Derivative Liability and Fair V

Derivative Liability and Fair Value Measurement	6 Months Ended
	Feb. 28, 2022
Derivative Liability And Fair Value Measurement
Derivative Liability and Fair Value Measurement	Note 10. Derivative Liability and Fair Value Measurement Upon the issuance of the convertible promissory notes with variable conversion prices and fixed conversion prices with reset provisions, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares would be available to settle all potential future conversion transactions. At the issuance date of the convertible notes payable during the six months ended February 28, 2022, the Company estimated the fair value of all embedded derivatives of $ 2,742,372 0 277 315 0.07 1.07 0.50 1.0 On February 28, 2022, the Company estimated the fair value of the embedded derivatives of $ 1,942,485 0 264 0.10 0.24 0.06 0.95 The Company adopted the provisions of ASC 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value. • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; • Level 2 — Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. As of February 28, 2022, the Company did not have any derivative instruments that were designated as hedges. Items recorded or measured at fair value on a recurring basis in the accompanying financial statements consisted of the following items as of February 28, 2022 and August 31, 2021: Fair Value, Assets Measured on Recurring Basis February 28, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability $ 1,942,485 $ — $ — $ 1,942,485 August 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability $ 4,747,614 $ — $ — $ 4,747,614 The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the six months ended February 28, 2022: Summary of changes in fair value of Level 3 financial liabilities Balance, August 31, 2021 $ 4,747,614 Transfers in due to issuance of convertible promissory notes 2,742,372 Transfers out due to conversions of convertible promissory notes (2,058,941 ) Change in derivative liability for the six months ended February 28, 2022 (3,488,560 ) Balance, February 28, 2022 $ 1,942,485 The total impact to the Company’s consolidated statement of operations for the six months ended February 28, 2022 was a gain of $ 3,488,560 Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in higher fair value measurement. A 10% change in pricing inputs and changes in volatilities and correlation factors would not result in a material change in our Level 3 fair value.

Common Stock

Common Stock	6 Months Ended
	Feb. 28, 2022
Equity [Abstract]
Common Stock	Note 11. Common Stock As of February 28, 2022, there were 509,142,691 509,142,691 shares of Common Stock issued and outstanding. On October 13, 2021, the Company amended its articles of incorporation to increase the number of authorized common shares to 1,000,000,000 On January 6, 2022, the Company amended its articles of incorporation to increase the number of authorized common shares to 2,000,000,000 On January 3, 2022, the Company entered into a Securities Purchase Agreement in connection with the issuance of a 10 100,000 3,000,000 25,200 On January 26, 2022, the Company issued 75,000,000 135,000 165,000 On February 15, 2022, the Company amended its articles of incorporation to increase the number of authorized common shares to 3,000,000,000 On February 22,2022, the Company received notices to exercise 24,804,305 23,300,000 During the six months ended February 28, 2022, the Company issued 51,181,398 367,750 14,710 During the six months ended February 28, 2022, the Company issued 268,394,475 1,163,334 76,569 During the six months ended February 28, 2022, the Company issued a total of 3,326,790 89,374

Preferred Stock

Preferred Stock	6 Months Ended
	Feb. 28, 2022
Equity [Abstract]
Preferred Stock	Note 12. Preferred Stock There are 10,000,000 0.0001 8,000,000 Holders of Series A Preferred Stock shall be entitled to 50 votes for every Share of Series A Preferred Stock 2,000,000 6,000,000 On February 28, 2021, the Company designated 1,000,000 367,750 153,500 350,000

Subsequent Events

Subsequent Events	6 Months Ended
	Feb. 28, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events Subsequent to February 28, 2022, the Company repaid $ 127,000 43,013 Subsequent to February 28, 2022, the Company sold 20,000,000 13,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Feb. 28, 2022
Accounting Policies [Abstract]
Derivative Instruments	Derivative Instruments The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in the fair value of derivatives liability are recorded in the consolidated statement of operations under non-operating income (expense). We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, we use a weighted average Binomial option-pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and NPE, in which the Company controls 56.4% of the common stock. All intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution.
Inventory	Inventory Inventory is primarily comprised of work in progress. Inventory is valued at cost, based on the specific identification method, unless and until the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to market value. As of February 28, 2022, and August 31, 2021, market values of all of our inventory were at cost, and accordingly, no
Deposits	Deposits Deposits is comprised of advance payments made to third parties, primarily for inventory for which we have not yet taken title. When we take title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale (see “Costs of Revenues” below). There were no
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets is primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods, which approximate the life of the contract or service period.
Accounts Receivable	Accounts Receivable Accounts receivables are recorded at the net value of face amount less any allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and, based on a method of specific identification of any accounts receivable for which we deem the net realizable value to be less than the gross amount of accounts receivable recorded, we establish an allowance for doubtful accounts for those balances. In determining our need for an allowance for doubtful accounts, we consider historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate, resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that we collect retainers from our clients prior to performing significant services. The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of February 28, 2022, and August 31, 2021, we had $ 0
Property and Equipment, net	Property and Equipment, net Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Depreciation of capitalized construction in progress costs, a component of property and equipment, net, begins once the underlying asset is placed into service and is recognized over the estimated useful life. Property and equipment are reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.”
Accounting for the Impairment of Long-Lived Assets	Accounting for the Impairment of Long-Lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets.
Beneficial Conversion Feature	Beneficial Conversion Feature If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). We record a BCF as a debt discount pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ACF”) Topic 470-20 Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and we amortize the discount to interest expense over the life of the debt using the effective interest method.
Revenue Recognition	Revenue Recognition For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The guidance presents a single five-step model for comprehensive revenue recognition that requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Two options are available for implementation of the standard which is either the retrospective approach or cumulative effect adjustment approach. The guidance becomes effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We determined to implement the cumulative effect adjustment approach to our implementation of FASB ASC Topic 606, with no restatement of the comparative periods presented. We intend to apply this method to any incomplete contracts we determine are subject to FASB ASC Topic 606 prospectively. As is more fully discussed below, we are of the opinion that none of our contracts for services or products contain significant financing components that require revenue adjustment under FASB ASC Topic 606. In accordance with FASB ASC Topic 606, Revenue Recognition, we will recognize revenue when persuasive evidence of a significant financing component exists in our consulting and product sales contracts. We examine and evaluate when our customers become liable to pay for goods and services; how much consideration is paid as compared to the cash selling price of the goods or services; and, the length of time between our performance and the receipt of payment.
Product Sales	Product Sales Revenue from product sales, including delivery fees, is recognized when an order has been obtained from the customer, the price is fixed and determinable when the order is placed, the product is shipped, and collectability is reasonably assured. For any shipments with destination terms, the Company defers revenue until delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606.
Costs of Revenues	Costs of Revenues Our policy is to recognize the costs of revenue in the same manner in conjunction with revenue recognition. Costs of revenues include the costs directly attributable to revenue recognition and include compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.
Stock-Based Compensation	Stock-Based Compensation Restricted shares are awarded to employees and entitle the grantee to receive shares of restricted common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date. Stock-based compensation during the quarterly reporting periods ended February 28, 2022 and 2021 was $ 89,374 522,334
Income Taxes	Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. For the quarterly reporting periods ending February 28, 2022 and 2021, we incurred no income taxes and had no liabilities related to federal or state income taxes.
Loss Contingencies	Loss Contingencies From time to time the Company is subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the balance sheet. If the Company determines that such an estimate cannot be made, the Company's policy is to disclose a demonstration of its attempt to estimate the loss or range of losses before concluding that an estimate cannot be made, and to disclose it in the notes to the financial statements under Contingent Liabilities.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share We report net income (loss) per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net income (loss) per share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted net income (loss) per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.

Acquisition of Natural Plant _2

Acquisition of Natural Plant Extract of California, Inc. (Tables)	6 Months Ended
	Feb. 28, 2022
Acquisition Of Natural Plant Extract Of California Inc.
Schedule of Preliminary Purchase Price Allocation	Schedule of Preliminary Purchase Price Allocation Purchase Price Allocation: Cash 2,200 Accounts receivable 193,607 Notes receivable 162,247 Property and equipment 1,153,000 Right of use asset – operating lease 673,425 Trademarks and trade names, estimated 5 year life 300,000 Licenses, estimated 10 year life 1,500,000 Customer relationships, estimated 5 year life 2,300,000 Goodwill 7,925,000 Total assets acquired $ 14,209,479 Accounts payable and accrued expenses 289,591 Right of use liability – operating lease 673,425 Notes payable 1,825,101 Notes payable – related party 105,539 Total Liabilities Assumed $ 2,893,656

Derivative Liability and Fair_2

Derivative Liability and Fair Value Measurement (Tables)	6 Months Ended
	Feb. 28, 2022
Derivative Liability And Fair Value Measurement
Fair Value, Assets Measured on Recurring Basis	Fair Value, Assets Measured on Recurring Basis February 28, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability $ 1,942,485 $ — $ — $ 1,942,485 August 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability $ 4,747,614 $ — $ — $ 4,747,614
Summary of changes in fair value of Level 3 financial liabilities	Summary of changes in fair value of Level 3 financial liabilities Balance, August 31, 2021 $ 4,747,614 Transfers in due to issuance of convertible promissory notes 2,742,372 Transfers out due to conversions of convertible promissory notes (2,058,941 ) Change in derivative liability for the six months ended February 28, 2022 (3,488,560 ) Balance, February 28, 2022 $ 1,942,485

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)

Jan. 03, 2022

Jun. 09, 2021

May 12, 2021

Feb. 22, 2022

Jan. 26, 2022

Feb. 16, 2021

Jan. 27, 2021

Nov. 16, 2020

Sep. 30, 2020

Aug. 31, 2020

Jul. 22, 2020

May 25, 2019

Feb. 28, 2022

Feb. 28, 2021

Feb. 28, 2022

Feb. 28, 2021

Jul. 01, 2019

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

3,000,000

Proceeds from sale of common stock

$ 177,000

Common stock, shares issued

3,000,000

23,300,000

75,000,000

51,181,398

Sale of Marketable Securities

$ 303,967

$ 0

Gain on Investment

$ (10,909)

$ 0

60,967

0

Settlement amount

$ 165,000

$ 0

Ethos Technology LLC [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Shares issued for business acquisition

6,000,000

NPE

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Gain on Investment

$ 359,391

Stock Purchase Agreement

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares issued

266,667

Shares issued for business acquisition

266,667

Stock Purchase Agreement | NPE

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Shares issued for business acquisition

266,667

Additional shares issued to related parties

1,436,368

Settlement Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock purchase price

$ 75,000,000

Cash contributed to joint venture

135,000

Settlement amount

165,000

Chief Executive Officer [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Accounts Payable

$ 1,000

Whisper [member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Restricted common stock

$ 150,000

Shareholder [Member] | Stock Purchase Agreement

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock purchase price

$ 2,040,000

Edward Manolos [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

1,500,000

Edward Manolos [Member] | Ethos Technology LLC [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Shares issued for business acquisition

1,500,000

Additional shares issued to related parties

1,500,000

Thang Nguyen [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

1,500,000

Thang Nguyen [Member] | Ethos Technology LLC [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Shares issued for business acquisition

1,500,000

Additional shares issued to related parties

1,500,000

Mr. Manolos

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Shares issued for business acquisition

266,667

Additional shares issued to related parties

11,383,929

Lauderdale Holdings, LLC [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares outstanding, percentage

70.70%

Lauderdale Holdings, LLC [Member] | Unaffiliated Parties [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

130,000,000

Proceeds from sale of common stock

$ 325,000

Lauderdale Holdings, LLC [Member] | Dan Nguyen [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

43,333,333

Proceeds from sale of common stock

$ 108,333

Lauderdale Holdings, LLC [Member] | Mr. Robert Hymers [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

43,333,333

Proceeds from sale of common stock

$ 108,333

Lauderdale Holdings, LLC [Member] | Edward Manolos [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

43,333,333

Proceeds from sale of common stock

$ 108,333

Marijuana Company of America, Inc [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock, shares sold

20,000,000

Shares issued for exchange of shares

7,222,222

Number of common stock exchanged

650,000,000

Value of common shares exchanged

$ 650,000

Restricted common stock issued

618,000

Cash contributed to joint venture

$ 135,000

$ 135,000

Going Concern Uncertainties (De

Going Concern Uncertainties (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	$ 14,015,507		$ 14,015,507		$ 13,891,788
Net income loss	$ 697,125	$ 2,100,770	329,047	$ 2,463,994
Net Cash Used in Operating Activities			$ 453,717	$ 774,444

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Aug. 31, 2021
Accounting Policies [Abstract]
Valuation allowance	$ 0		$ 0
Deposits	0
Allowance for doubtful accounts	0		$ 0
Stock Based Compensation	$ 89,374	$ 522,334

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details Narrative) - shares	1 Months Ended	6 Months Ended
	Dec. 29, 2021	Feb. 28, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of stock, shares converted	10,475,053
Common Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of stock, shares issued		604,448,320
Series B Convertible Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of stock, shares converted		142,089,094

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)	1 Months Ended
	Jun. 15, 2020shares
Lelantos [Member] | Modification Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Common stock obligations	400,000

Acquisition of Natural Plant _3

Acquisition of Natural Plant Extract of California, Inc. (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021	Feb. 16, 2021
Restructuring Cost and Reserve [Line Items]
Goodwill	$ 7,925,000	$ 8,842,967
NPE
Restructuring Cost and Reserve [Line Items]
Cash			$ 2,200
Accounts receivable			193,607
Notes receivable			162,247
Property and equipment			1,153,000
Right of use asset – operating lease			673,425
Trademarks and trade names, estimated 5 year life			300,000
Licenses, estimated 10 year life			1,500,000
Customer relationships, estimated 5 year life			2,300,000
Goodwill			7,925,000
Total assets acquired			14,209,479
Accounts payable and accrued expenses			289,591
Right of use liability – operating lease			673,425
Notes payable			1,825,101
Notes payable – related party			105,539
Total Liabilities Assumed			$ 2,893,656

Acquisition of Natural Plant _4

Acquisition of Natural Plant Extract of California, Inc. (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		6 Months Ended
	Aug. 31, 2021	Feb. 16, 2021	Jan. 27, 2021	Aug. 31, 2020	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	Jun. 11, 2021	Aug. 21, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest rate	10.00%
Principal amount									$ 440,000
Gain loss on investment					$ (10,909)	$ 0	$ 60,967	$ 0
Fair value of assets and liabilities					$ 934,868		934,868
Non-controlling interest							$ 4,926,000
Mr. Manolos
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for business acquisition			266,667
Additional fair value			$ 1,821,429
Additional shares issued to related parties			11,383,929
NPE
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value adjustment		$ 3,324,956
Gain loss on investment		359,391
Non-controlling interest		$ 454,768
Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for business acquisition				266,667
Stock Purchase Agreement | NPE
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for business acquisition		266,667
Ownership percentage										4.99%
Debt discount										$ 270,886
Initial investment										$ 1,714,903
Additional shares issued to related parties		1,436,368

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 09, 2021	Jan. 27, 2021	Nov. 16, 2020	Feb. 28, 2022	Feb. 28, 2021	Aug. 31, 2018	Feb. 28, 2022	Feb. 28, 2021	Jan. 31, 2022	Aug. 31, 2021	May 25, 2019
Related Party Transaction [Line Items]
Note Payable				$ 890,441			$ 890,441			$ 975,043	$ 16,667
Interest Rate											5.00%
Common stock, shares sold			3,000,000
Proceeds from sale of common stock			$ 177,000
Sale of Marketable Securities							303,967	$ 0
Gain on Investment				$ (10,909)	$ 0		$ 60,967	$ 0
Marijuana Company of America, Inc [Member]
Related Party Transaction [Line Items]
Common stock, shares sold							20,000,000
Value of common shares exchanged	$ 650,000
Restricted common stock issued	618,000
Common Stock [Member]
Related Party Transaction [Line Items]
Issuance of shares									75,000,000
Ethos Technology LLC [Member]
Related Party Transaction [Line Items]
Shares issued for business acquisition			6,000,000
Legal custodian 2 [Member]
Related Party Transaction [Line Items]
Advances						$ 600
Interest rate						10.00%
Edward Manolos [Member]
Related Party Transaction [Line Items]
Common stock, shares sold			1,500,000
Edward Manolos [Member] | Ethos Technology LLC [Member]
Related Party Transaction [Line Items]
Shares issued for business acquisition			1,500,000
Additional shares issued to related parties			1,500,000
Thang Nguyen [Member]
Related Party Transaction [Line Items]
Common stock, shares sold			1,500,000
Thang Nguyen [Member] | Ethos Technology LLC [Member]
Related Party Transaction [Line Items]
Shares issued for business acquisition			1,500,000
Additional shares issued to related parties			1,500,000
Mr. Manolos
Related Party Transaction [Line Items]
Shares issued for business acquisition		266,667
Additional shares issued to related parties		11,383,929

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 11, 2021	Feb. 12, 2020	Feb. 28, 2022	Jan. 03, 2022	Aug. 31, 2021
Debt Instrument [Line Items]
Principal amount	$ 440,000
Maturity date	Jun. 11, 2022
Carrying value				$ 100,000
Accrued interest payable			$ 147,106		$ 212,202
Three Sellers Acquisition Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount		$ 500,000
Maturity date		May 31, 2020
Interest rate		8.00%
Gain for debt forgiveness		$ 50,747
Carrying value			450,000		450,000
Accrued interest payable			76,438		55,824
Compensation Promissory Note [Member] | Consultant [Member] | Consulting Agreement [Member]
Debt Instrument [Line Items]
Principal amount		$ 100,000
Carrying value			100,000		100,000
Accrued interest payable			$ 14,400		$ 12,405

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

Feb. 11, 2022

Jan. 06, 2022

Jan. 03, 2022

Aug. 04, 2021

Jun. 11, 2021

Mar. 08, 2021

Feb. 11, 2021

Jan. 12, 2021

Jan. 06, 2021

Jan. 03, 2021

Dec. 09, 2020

Oct. 09, 2020

Feb. 22, 2022

Jan. 26, 2022

Dec. 29, 2021

Sep. 22, 2021

Jun. 16, 2021

May 20, 2021

Mar. 16, 2021

Jan. 26, 2021

Aug. 31, 2020

Aug. 21, 2020

May 22, 2020

Apr. 30, 2020

Feb. 29, 2020

Feb. 28, 2022

Feb. 28, 2021

Aug. 04, 2022

Aug. 31, 2021

May 25, 2019

Principal amount

$ 440,000

Conversion price

$ 0.004

Proceeds from Convertible debt

$ 1,065,320

$ 1,086,000

Conversion of Stock, Amount Converted

$ 24,774

Conversion of Stock, Shares Converted

10,475,053

Carrying value

$ 100,000

Outstanding accounts payable

744,397

$ 730,825

Maturity date

Jun. 11, 2022

Accrued interest payable

$ 147,106

$ 212,202

Shares issued

3,000,000

23,300,000

75,000,000

51,181,398

Deferred financing costs

$ 25,200

Preferred stock, shares outstanding

6,000,000

6,000,000

Note payable

$ 890,441

$ 975,043

$ 16,667

Chief Executive Officer [Member]

Principal amount

$ 79,333

Robert L. Hymers III [Member]

Principal amount

$ 53,768

Chief Financial Officer [Member]

Interest rate

10.00%

Interest expense

$ 30,000

Maturity date

Dec. 31, 2020

Series B Convertible Preferred Stock [Member]

Conversion of Stock, Shares Converted

142,089,094

Carrying value

$ 172,142

Debt discount

105,358

Accrued interest payable

$ 24,336

Preferred stock, shares outstanding

277,750

367,750

Five Series B Preferred Stock [Member]

Interest expense

$ 277,500

Two Convertible Promissory Notes [Member]

Interest rate

10.00%

Principal amount

$ 133,101

Interest expense

$ 133,101

Principal [Member] | Chief Financial Officer [Member]

Conversion of Stock, Shares Converted

1,500,000

Stock Purchase Agreement

Shares issued

266,667

Stock Purchase Agreement | NPE

Debt discount

$ 270,886

Debt default

540,000

Initial investment

$ 1,714,903

Accredited Investor 1 [Member] | Securities Purchase Agreement [Member]

Interest rate

10.00%

Principal amount

$ 115,500

Conversion price

$ 0.10

Proceeds from Convertible debt

$ 100,000

Interest expense

$ 115,500

Accredited Investor 1 [Member] | Securities Purchase Agreement [Member] | Principal [Member]

Conversion of Stock, Amount Converted

40,000

Accredited Investor 1 [Member] | Securities Purchase Agreement [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 3,112

Accredited Investor 2 [Member] | Securities Purchase Agreement [Member]

Conversion of Stock, Shares Converted

11,446,165

Accredited Investor 2 [Member] | Securities Purchase Agreement [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 118,875

Accredited Investor 2 [Member] | Securities Purchase Agreement [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 9,543

Accredited Investor 2 [Member] | Securities Purchase Agreements [Member]

Interest rate

10.00%

Principal amount

$ 243,875

Proceeds from Convertible debt

215,500

Interest expense

$ 243,875

Accredited Investor 2 [Member] | Second Securities Purchase Agreements [Member]

Interest rate

10.00%

Principal amount

$ 243,875

Proceeds from Convertible debt

215,500

Interest expense

$ 243,875

Conversion of Stock, Shares Converted

27,063,391

208,191

Accredited Investor 2 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 228,875

$ 15,000

Accredited Investor 2 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 14,307

2,250

Accredited Investor 3 [Member] | Securities Purchase Agreements [Member]

Interest rate

10.00%

Principal amount

$ 215,000

Accredited Investor 3 [Member] | Second Securities Purchase Agreements [Member]

Proceeds from Convertible debt

191,000

Interest expense

$ 215,000

Conversion of Stock, Shares Converted

81,397,959

Accredited Investor 3 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 270,250

Accredited Investor 3 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 21,276

Accredited Investor 4 [Member] | Securities Purchase Agreement [Member]

Interest rate

10.00%

Principal amount

$ 215,000

Proceeds from Convertible debt

191,000

Interest expense

$ 215,000

Accredited Investor 4 [Member] | Second Securities Purchase Agreements [Member]

Conversion of Stock, Shares Converted

30,087,611

Accredited Investor 4 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 215,000

Accredited Investor 4 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 12,372

Accredited Investor 5 [Member] | Securities Purchase Agreement [Member]

Interest rate

8.00%

Principal amount

$ 130,000

Proceeds from Convertible debt

108,000

Interest expense

$ 130,000

Accredited Investor 5 [Member] | Second Securities Purchase Agreements [Member]

Conversion of Stock, Shares Converted

46,880,909

Accredited Investor 5 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 130,000

Accredited Investor 5 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 6,261

Accredited Investor 6 [Member] | Securities Purchase Agreement [Member]

Interest rate

8.00%

Principal amount

$ 135,000

Proceeds from Convertible debt

108,000

Interest expense

$ 130,000

Accredited Investor 6 [Member] | Second Securities Purchase Agreements [Member]

Conversion of Stock, Shares Converted

14,912,584

Accredited Investor 6 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 47,560

Carrying value

28,262

Debt discount

4,069

Accrued interest

0

Accredited Investor 6 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

2,440

Accredited Investor 7 [Member] | Securities Purchase Agreement [Member]

Interest rate

8.00%

Principal amount

$ 110,000

Interest expense

110,000

Net proceeds

$ 89,000

Accredited Investor 7 [Member] | Second Securities Purchase Agreements [Member]

Conversion of Stock, Shares Converted

21,910,886

Accredited Investor 7 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 48,000

Accredited Investor 7 [Member] | Second Securities Purchase Agreements [Member] | Interest [Member]

Conversion of Stock, Amount Converted

$ 1,957

Vendor [Member] | Convertible Promissory Note [Member]

Principal amount

$ 25,000

Carrying value

25,000

Outstanding accounts payable

$ 21,000

Maturity date

Mar. 22, 2022

Accrued interest payable

1,089

Accredited Investor 8 [Member] | Securities Purchase Agreement [Member]

Interest rate

10.00%

Principal amount

$ 100,000

Interest expense

120,000

Net proceeds

$ 80,000

Shares issued

3,000,000

Deferred financing costs

$ 25,200

Accredited Investor 8 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Carrying value

15,342

Debt discount

84,658

Accrued interest

$ 1,584

Accredited Investor 9 [Member] | Securities Purchase Agreement [Member]

Interest rate

8.00%

Principal amount

$ 120,000

Interest expense

120,000

Net proceeds

$ 102,000

Accredited Investor 9 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Carrying value

18,411

Debt discount

101,589

Accrued interest

$ 1,394

Accredited Investor 10 [Member] | Securities Purchase Agreement [Member]

Interest rate

8.00%

Principal amount

$ 130,000

Interest expense

130,000

Net proceeds

$ 110,400

Accredited Investor 10 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Carrying value

19,945

Debt discount

110,055

Accrued interest

$ 484

Accredited Investor 11 [Member] | Securities Purchase Agreement [Member]

Interest rate

12.00%

Principal amount

$ 615,000

Conversion price

$ 0.0025

Interest expense

615,000

Net proceeds

$ 512,820

Accredited Investor 11 [Member] | Second Securities Purchase Agreements [Member] | Principal [Member]

Carrying value

94,356

Debt discount

520,644

Accrued interest

$ 3,437

Accredited Investor 5 [Member] [Default Label] | Second Securities Purchase Agreements [Member]

Interest expense

367,750

Conversion of Stock, Amount Converted

$ 367,750

Conversion of Stock, Shares Converted

51,181,398

Accrued interest payable

$ 14,710

Accredited Investo 6 [Member] | Three Securities Purchase Agreements [Member]

Interest expense

260,000

Cash received

260,000

Tabatabaei [Member] | Two Convertible Promissory Notes [Member]

Conversion of Stock, Shares Converted

694,902

Gain on conversion

$ 10,468

Tabatabaei [Member] | Two Convertible Promissory Notes [Member] | Chief Financial Officer [Member]

Carrying value

15,884

Debt discount

37,884

Accrued interest payable

$ 3,138

Tabatabaei [Member] | Principal [Member] | Two Convertible Promissory Notes [Member]

Conversion of Stock, Amount Converted

79,333

Tabatabaei [Member] | Interest [Member] | Two Convertible Promissory Notes [Member]

Conversion of Stock, Amount Converted

$ 2,608

Robert L. Hymers III [Member]

Interest rate

10.00%

Conversion of Stock, Shares Converted

878,190

Accrued interest payable

86,203

Robert L. Hymers III [Member] | Principal [Member]

Conversion of Stock, Amount Converted

$ 53,768

Note payable principal amount

690,000

Robert L. Hymers III [Member] | Interest [Member]

Accrued interest payable

$ 4,626

Chief Financial Officer [Member]

Conversion price

$ 0.02

Carrying value

$ 15,061

Debt discount

14,939

Accrued interest payable

$ 1,011

NPE | Stock Purchase Agreement

Stock Issued During Period, Shares, Acquisitions

266,667

Mr. Hymers [Member]

Accrued interest

2,476

Exchange agreement, description

Company authorized and entered into an exchange agreement with Mr. Hymers to exchange the remaining $690,000 principal and $164,156 of accrued interest into a new $854,156 note (“exchange note”). The exchange note is convertible at a fixed price of $0.0025 per share and matures on February 11, 2023.

Note payable

854,156

Robert L Hymers [Member]

Conversion of Stock, Amount Converted

$ 40,000

Conversion of Stock, Shares Converted

17,543,860

Carrying value

$ 275,836

Debt discount

124,164

Accrued interest payable

$ 29,600

Derivative Liability and Fair_3

Derivative Liability and Fair Value Measurement (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	$ 1,942,485	$ 4,747,614
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	$ 1,942,485	$ 4,747,614

Derivative Liability and Fair_4

Derivative Liability and Fair Value Measurement (Details 1)	6 Months Ended
	Feb. 28, 2022USD ($)
Derivative Liability And Fair Value Measurement
Balance at beginning	$ 4,747,614
Transfers in due to issuance of convertible promissory notes	2,742,372
Transfers out due to conversions of convertible promissory notes	(2,058,941)
Change in derivative liability for the three months ended November 30, 2021	(3,488,560)
Balance at end	$ 1,942,485

Derivative Liability and Fair_5

Derivative Liability and Fair Value Measurement (Details Narrative)	6 Months Ended
	Feb. 28, 2022USD ($)
Debt Instrument [Line Items]
Fair value of embedded derivatives	$ 1,942,485
Dividend yield	0.00%
Expected volatility	264.00%
Changes in fair value of derivatives	$ 3,488,560
Minimum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	0.10%
Expected life (in years)	21 days
Maximum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	0.24%
Expected life (in years)	11 months 12 days
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Fair value of embedded derivatives	$ 2,742,372
Dividend yield	0.00%
Convertible Notes Payable [Member] | Minimum [Member]
Debt Instrument [Line Items]
Expected volatility	277.00%
Risk-free interest rate	0.07%
Expected life (in years)	6 months
Convertible Notes Payable [Member] | Maximum [Member]
Debt Instrument [Line Items]
Expected volatility	315.00%
Risk-free interest rate	1.07%
Expected life (in years)	1 year

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	Jan. 03, 2022	May 12, 2021	Feb. 22, 2022	Jan. 26, 2022	Dec. 29, 2021	Feb. 28, 2022	Apr. 10, 2022	Feb. 15, 2022	Jan. 06, 2022	Oct. 13, 2021	Aug. 31, 2021
Class of Stock [Line Items]
Common stock, shares issued						509,142,691					84,940,028
Common stock, shares outstanding						509,142,691					84,940,028
Common stock, shares authorized						3,000,000,000		3,000,000,000	2,000,000,000	1,000,000,000	3,000,000,000
Interest rate	10.00%
Principal amount	$ 100,000
Issuance of shares	3,000,000		23,300,000	75,000,000		51,181,398
Deferred financing costs	$ 25,200
Recognized loss				$ 165,000
Warrants			24,804,305
Conversion of Stock, Amount Converted						$ 14,710
Conversion of Stock, Amount Converted					$ 24,774
Shares issued for services						3,326,790
Shares issued for services amount						$ 89,374
Three Lenders [Member]
Class of Stock [Line Items]
Issuance of shares						268,394,475
Conversion of Stock, Amount Converted						$ 76,569
Conversion of Stock, Amount Converted						1,163,334
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Principal amount						$ 172,142
Conversion of stock, shares issued value						367,750
Marijuana Company of America, Inc [Member]
Class of Stock [Line Items]
Cash contributed to joint venture		$ 135,000		$ 135,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares issued							509,142,691
Common stock, shares outstanding							509,142,691

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Jan. 03, 2022	Feb. 22, 2022	Jan. 26, 2022	May 28, 2020	Dec. 16, 2019	Feb. 28, 2022	Aug. 31, 2021	Feb. 28, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized						10,000,000	10,000,000
Preferred stock, par or stated value per share						$ 0.0001	$ 0.0001
Preferred stock, shares issued						6,000,000	6,000,000
Preferred stock, shares outstanding						6,000,000	6,000,000
Shares issued	3,000,000	23,300,000	75,000,000			51,181,398
Proceeds from Issuance of Preferred Stock						$ 350,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					8,000,000
Preferred stock, voting right					Holders of Series A Preferred Stock shall be entitled to 50 votes for every Share of Series A Preferred Stock
Shares returned during the period				2,000,000
Preferred stock, shares issued								6,000,000
Preferred stock, shares outstanding								6,000,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized						1,000,000	1,000,000
Preferred stock, shares issued						277,750	367,750
Preferred stock, shares outstanding						277,750	367,750
Series B Preferred Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Shares issued						367,750
Purchase Price							$ 153,500

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Nov. 16, 2020	Feb. 28, 2022
Repayment of debt		$ 127,000
Sale of stock	3,000,000
Total proceeds		$ 13,000
Marijuana Company of America, Inc [Member]
Sale of stock		20,000,000
Five Series B Preferred Stock [Member]
Debt interest amount		$ 43,013